Stanford University


Showing 561-570 of 7,961 Results

  • Lina Margareta Bertling Tjernberg

    Lina Margareta Bertling Tjernberg

    Visiting Professor, Energy Science & Engineering

    BioLina Bertling Tjernberg is Professor in Power Grid Technology at KTH Royal Institute of Technology, Sweden, and Visiting Professor in the Department of Energy Science and Engineering at Stanford University during 2026–2027. Her research focuses on the reliability and resilience of future electric power systems, with particular emphasis on predictive maintenance, reliability-centered asset management, and risk-informed decision support. At Stanford, her research explores resilient power grids, robust optimization, and approaches combining power-system engineering with data-driven and AI-enabled methods.

  • Carolyn Bertozzi

    Carolyn Bertozzi

    Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology

    BioCarolyn Bertozzi is the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University and became the co-director and Institute Scholar at Sarafan ChEM-H.

    Prof. Bertozzi's research focuses on fundamental studies of disease-associated glycobiology and the development of new therapeutic modalities that target these pathways. Her inventions include bioorthogonal chemistries for in vivo imaging and bioconjugation, work for which she received the 2022 Nobel Prize in Chemistry. As well, her lab has developed next generation antibody-drug conjugates, lysosome-targeting chimeras (LYTACs), antibody-enzyme conjugates and antibody-lectin chimeras. Several of these new therapeutic modalities have been translated into clinical candidates for treatment of cancer and autoimmune diseases.

    In addition to the Nobel Prize, Prof. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. For example, she is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Inventors Academy and the National Academy of Engineering, the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, and she is a Foreign Fellow of the Royal Society. In addition, Prof. Bertozzi received the Priestley Medal of the American Chemical Society, the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, Lemelson-MIT award for inventors, and a MacArthur "Genius Award".

  • Allison Betof, MD, PhD, FASCO

    Allison Betof, MD, PhD, FASCO

    Associate Professor of Medicine (Oncology)

    BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.

  • Eric Bettinger

    Eric Bettinger

    Conley DeAngelis Family Professor, Professor of Education, Senior Fellow at the Hoover Institution and at the Stanford Institute for Economic Policy Research and Professor, by courtesy, of Economics at the Graduate School of Business

    Current Research and Scholarly InterestsEric's research interests include economics of education; pathways into the labor market; development of socio-emotional skills; student success and completion in college; the impacts of online education; the impacts of financial aid; other determinants of student success in college; effects of voucher programs on both academic and non-academic outcomes. His research focuses on using rigorous statistical methods in identifying cause-and-effect relationships in higher education.

  • Jill Beyer, OD

    Jill Beyer, OD

    Clinical Associate Professor, Ophthalmology

    BioJill Beyer, OD, is a Clinical Assistant Professor at Stanford University School of Medicine.

    Dr. Beyer graduated from Southern California College of Optometry, earning her Doctor of Optometry degree with distinction. She completed her residency at New England College of Optometry in Boston, Massachusetts, and earned a Bachelor of Science degree in Biology from Oregon State University.

    Jill’s residency education included time spent at the Boston Foundation for Sight, Massachusetts Eye and Ear Infirmary, Cornea Consultants & Boston Laser Center, and Harvard Vanguard Medical Associates.

    After residency training, Jill continued on as a clinical preceptor at the New England College of Optometry while working in private practice in Boston. She then transitioned to full time academic work at the Massachusetts Eye and Ear Infirmary becoming the Director of the Contact Lens Department and an Instructor in Ophthalmology at Harvard Medical School.

  • Gala Beykin, MD

    Gala Beykin, MD

    Clinical Instructor, Ophthalmology

    BioDr. Beykin is an ophthalmologist and glaucoma specialist at the Byers Eye Institute at Stanford Health Care. She is also a clinical instructor in the Department of Ophthalmology at Stanford University School of Medicine.

    Dr. Beykin completed clinical and surgical training in glaucoma at the Byers Eye Institute. She specializes in caring for patients with all types of ophthalmic conditions, including glaucoma and cataract.

    She has expertise in clinical trial design and implementation, and studies novel biomarkers and candidate therapeutics for vision protection and restoration in glaucoma. Her research efforts include numerous clinical trials investigating new therapies for eye conditions. Dr. Beykin has participated in multiple studies evaluating drugs targeting retinal disease such as AMD and diabetes-related vision loss, as well as ongoing clinical trials assessing new treatment strategies for neuroprotection, neuroregeneration and neuroenhancement in glaucoma. These include implants that could potentially stop or slow the progression of and help improve vision.

    Dr. Beykin has published her work in numerous peer-reviewed journals, including the British Journal of Ophthalmology and Investigative Ophthalmology & Visual Science. She has presented her work at national and international meetings, including those for the International Symposium on Retinal Degeneration and the Association for Research in Vision and Ophthalmology.

    She is a member of the Israeli Ophthalmology Society, the Israeli Society for Eye and Vision Research, and the Association for Research in Vision and Ophthalmology.